绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20211109002 | --- | --- | --- | --- | |---------------------------|---------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------| | 证券简称：绿康生化 证券代码： | 002868 | 编号： 20211215005 | | | □特定对象调研 | □分析师会 ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20220210002 | --- | --- | --- | --- | --- | |--------------------|----------------------|------------------------------------------------------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20220209001 | --- | --- | --- | |-------------------------------|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20220217003 | --- | --- | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's revenue for Q3 2022 was ¥89,802,349, representing a 14.68% increase compared to the same period last year[5]. - Total operating revenue for Q3 2022 was ¥234,068,484.09, a decrease of 7.5% compared to ¥252,150,180.35 in the same period last year[37]. - The net profit attributable to shareholders was -¥31,243,901.96, a decrease of 149.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥28,126,768.03, a decline of 539.52% compared to the previous year[5]. - Net loss for Q3 2022 was ¥68,093,068.62, compared to a net loss of ¥6,130,103.51 in Q3 2021, reflecting a significant decline in profitability[38]. - The total comprehensive income for the third quarter was -68,093,068.62 CNY, with a loss attributable to the parent company of -67,776,031.12 CNY[39]. - Basic and diluted earnings per share were both -0.44 CNY, compared to -0.04 CNY in the previous period[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,267,040,394.85, an increase of 0.69% from the end of the previous year[5]. - The company's total assets increased slightly to ¥1,267,040,394.85 from ¥1,258,398,896.70, showing stability in asset base despite losses[35]. - Total liabilities increased to ¥613,111,256.49 from ¥536,376,689.72, reflecting a growing debt burden[35]. - The company's cash and cash equivalents decreased from ¥97,495,450.53 to ¥34,717,251.56, indicating a liquidity challenge[34]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥13,515,864.69, a significant decrease of 4,342.38%[5]. - Cash inflow from operating activities totaled 302,118,093.41 CNY, an increase from 283,909,384.26 CNY in the previous period[42]. - The net cash flow from operating activities was -13,515,864.69 CNY, a significant decrease from 318,591.85 CNY in the previous period[42]. - Cash outflow from investing activities was 122,549,264.25 CNY, down from 242,961,229.25 CNY in the previous period[42]. - The net cash flow from financing activities was 69,264,478.11 CNY, compared to 164,938,738.37 CNY in the previous period[42]. - The ending balance of cash and cash equivalents was 34,717,251.56 CNY, down from 121,971,243.74 CNY in the previous period[42]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,457[16]. - Shanghai Kangyi Investment Co., Ltd. holds 30.43% of shares, totaling 47,291,400 shares, with 8,000,000 shares pledged[16]. - He Li (Asia) Investment Co., Ltd. holds 26.70% of shares, totaling 41,489,860 shares[16]. - The top ten shareholders include several domestic and foreign entities, with significant stakes held by Shanghai Kangyi and He Li Investment[17]. Investment and Acquisitions - The company plans to issue up to 46,624,751 shares in a non-public offering, which will not exceed 30% of the total share capital before the issuance[19]. - The total amount of funds to be raised from the non-public offering is expected to be no more than 305 million RMB[19]. - The acquisition of 100% equity in Jiangxi Wei Ke New Materials Technology Co., Ltd. is contingent upon the successful completion of the share transfer and asset sale[24]. - The deadline for the asset acquisition agreement has been extended to November 28, 2022, allowing for further negotiations[26]. - The company has suspended the share transfer and asset sale due to the need for further discussions among involved parties[25]. - The asset transfer is subject to audit and evaluation, with the transaction price yet to be determined, posing risks of termination if agreements cannot be reached[29]. - The asset acquisition agreement stipulates that if the transaction price is below 95 million yuan, the counterparty has the right to terminate the agreement[29]. Operational Challenges - The company's inventory increased by 72.52% to ¥105,587,860.43, indicating a rise in product stock at the end of the period[9]. - Accounts receivable increased to ¥55,386,102.48 from ¥44,031,827.95, suggesting potential issues with collections[34]. - Inventory levels rose significantly to ¥105,587,860.43 from ¥61,204,853.85, indicating potential overstocking or declining sales[34]. - The company reported a substantial increase in financial expenses, with interest expenses rising to ¥8,205,399.45 from ¥1,387,033.25[38]. - The company has not reported any net profit from mergers under common control, indicating no contribution from such activities[35]. Regulatory and Compliance - The non-public offering was approved by the China Securities Regulatory Commission (CSRC) on June 16, 2021[21]. - The approval for the non-public offering expired due to the inability to complete the issuance within 12 months, but it will not significantly impact the company's operations[22]. - The company has extended the validity period for the non-public offering resolution until February 18, 2023[21]. - The company has not yet issued a new notice for the shareholders' meeting regarding the share transfer, indicating significant uncertainty about approval[28]. - The implementation of the share transfer and asset sale is interdependent; failure of one will prevent the execution of the others[29]. - The company emphasizes the importance of timely information disclosure to investors regarding the progress of these transactions[26].

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders for the same period was 80 million RMB, up 20% compared to the previous year[18]. - The company's revenue for the first half of 2022 was ¥144,266,135.09, a decrease of 17.01% compared to ¥173,844,094.41 in the same period last year[23]. - The net profit attributable to shareholders was -¥36,532,129.16, representing a decline of 656.46% from ¥6,565,087.10 in the previous year[23]. - The company reported a total profit of -43,463,603.44 CNY and a net profit attributable to shareholders of -36,532,129.16 CNY for the reporting period, primarily due to high costs associated with the veterinary drug investment project and the cogeneration project, as well as reduced sales revenue impacted by the Shanghai COVID-19 outbreak[47]. - The basic and diluted earnings per share were both -¥0.24, reflecting a decrease of 700.00% from ¥0.04 in the same period last year[23]. - The company reported a net loss for the first half of 2022 was CNY 36,658,331.41, compared to a net profit of CNY 6,485,648.32 in the first half of 2021[186]. - The total comprehensive loss for the first half of 2022 was CNY -36,658,331.41, compared to a comprehensive income of CNY 6,485,821.99 in the first half of 2021[186]. Market Expansion and Product Development - The company plans to launch two new products in Q4 2022, aiming to capture a larger market share in the biochemistry sector[18]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region by the end of 2022[18]. - The company focuses on expanding its product structure and actively developing both domestic and international markets[38]. - The company plans to complete the annual production project of 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials by March 31, 2022[56]. - The company is actively pursuing an "internal + external" growth strategy to achieve sustainable development, focusing on the research and improvement of existing products and the registration of veterinary drugs to meet future market demands[48]. - Future guidance indicates a projected revenue growth of 10-15% for the second half of 2022[18]. Research and Development - Research and development expenses increased by 12%, reflecting the company's commitment to innovation and new technology[18]. - The company has accumulated 18 invention patents and 15 utility model patents, showcasing its commitment to innovation in the field of veterinary medicine[40]. - The company has allocated resources for research and development to enhance its product offerings and technological capabilities[197]. Financial Position and Cash Flow - The net cash flow from operating activities improved to ¥7,409,002.21, a significant increase of 140.37% compared to -¥18,353,447.83 in the same period last year[23]. - The company's total assets decreased by 1.49% to ¥1,239,692,295.94 from ¥1,258,398,896.70 at the end of the previous year[23]. - The net assets attributable to shareholders fell by 5.09% to ¥681,094,869.76 from ¥717,626,998.92 at the end of the previous year[23]. - Cash and cash equivalents decreased to ¥34,763,555.82, representing 2.80% of total assets, down from 7.75% in the previous year, a decrease of 4.95%[68]. - The company reported a significant increase in long-term equity investments to CNY 28,263,078.21 from CNY 34,713,691.52, indicating a decrease of approximately 18.7%[177]. - The total liabilities rose to CNY 554,328,420.37 from CNY 536,376,689.72, indicating an increase of about 3.6%[178]. Risk Management - The management highlighted potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[5]. - The company is addressing risks related to major customer procurement fluctuations by expanding its domestic market presence and developing new products[85]. - The company is actively managing environmental risks by implementing wastewater treatment and emissions monitoring systems[86]. - The company has approved a foreign exchange hedging business with a limit of up to $50 million to mitigate currency fluctuation risks[87]. Environmental and Social Responsibility - The company has established a wastewater treatment workshop at the Nanpu plant, with online monitoring of pollutants such as COD and ammonia nitrogen[100]. - The company has been actively promoting green development and has engaged in community tree planting activities to enhance ecological awareness[108]. - The company established a "Love Fund" to support 9 impoverished families with a total donation of 30,000 yuan in 2022, and has provided 6,000 yuan for the education of children of deceased employees[109]. - The company actively participated in poverty alleviation efforts, contributing a total of 40,000 yuan to support rural development in 2022[110]. Shareholder and Corporate Governance - The company held its first extraordinary shareholders' meeting on February 7, 2022, with a participation rate of 43.27%[91]. - The annual shareholders' meeting on May 18, 2022, had a participation rate of 71.90%[91]. - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[6]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[92]. - The company has no equity incentive plans or employee stock ownership plans in place[95]. Legal and Compliance Issues - The company is involved in litigation with a total amount of approximately 1,455.97 million yuan related to operational guarantees and interest payments[120]. - The company is also pursuing claims against Green Health Biochemical Co., Ltd. for a total of 2,607.31 million yuan, which includes compensation for equipment failures and economic losses[120]. - The company has not experienced any major litigation or arbitration matters during the reporting period[119].

Financial Performance - The company's revenue for Q1 2022 was ¥62,687,107.78, a decrease of 31.06% compared to ¥90,930,335.34 in the same period last year[2] - The net profit attributable to shareholders was a loss of ¥8,913,785.79, representing a decline of 471.12% from a profit of ¥2,401,830.67 in Q1 2021[2] - The company's basic and diluted earnings per share were both -¥0.06, a decrease of 400.00% compared to ¥0.02 in Q1 2021[2] - Net loss for Q1 2022 was ¥9,003,935.49, compared to a net profit of ¥2,294,256.78 in Q1 2021, indicating a significant decline in profitability[27] - The company's operating profit for Q1 2022 was -¥11,082,787.91, contrasting with an operating profit of ¥1,509,334.75 in the previous year[27] Cash Flow - The net cash flow from operating activities improved to ¥5,001,432.08, a 120.00% increase from a negative cash flow of ¥25,012,216.19 in the previous year[2] - Cash received from tax refunds was ¥23,801,853.00, a 407.92% increase from ¥4,686,184.98 in Q1 2021, primarily due to cumulative VAT refunds[8] - Total cash inflow from financing activities was ¥78,065,760.00, up from ¥37,919,160.40 in the same period last year[32] - The net cash flow from investing activities was -¥57,605,711.99, compared to -¥73,736,543.37 in Q1 2021, indicating a reduced cash outflow[31] - The company reported cash inflow from operating activities totaling ¥108,143,832.33, compared to ¥72,131,062.74 in Q1 2021, reflecting a year-over-year increase of approximately 50%[31] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,233,272,816.55, down 2.00% from ¥1,258,398,896.70 at the end of the previous year[2] - The company's total liabilities increased, with contract liabilities rising by 158.25% to ¥2,362,258.12 due to an increase in advance payments received[6] - The total liabilities as of the end of Q1 2022 were ¥520,254,732.54, a decrease from ¥536,376,689.72 at the end of the previous year[24] - The total equity attributable to shareholders of the parent company was ¥708,713,213.14, down from ¥717,626,998.92 in the previous year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,688[11] - Shanghai Kangyi Investment Co., Ltd. holds 30.43% of shares, totaling 47,291,400 shares, with 9,378,390 shares pledged[11] - Helix (Asia) Investment Co., Ltd. holds 26.70% of shares, totaling 41,489,860 shares[11] - The top ten shareholders include both domestic and foreign entities, with significant stakes held by non-state-owned legal persons[11] Government Subsidies and Investments - The company received government subsidies amounting to ¥1,082,490.80 during the quarter, which are closely related to its normal business operations[4] - The company plans to raise up to 305 million RMB through a non-public offering of up to 46,624,751 shares[13] - The project for producing 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials (sulfamethoxazole) was delayed and completed by March 31, 2022, with additional self-funded investment of up to RMB 80 million approved[17] - The total investment for the cogeneration project in the Pucheng Putan Industrial Park is approximately RMB 201.17 million, aimed at ensuring stable heating quality and reducing electricity costs[20] Operational Efficiency - The company plans to continue expanding its production capacity and improve operational efficiency through strategic investments and project completions[20] - Research and development expenses for Q1 2022 amounted to ¥5,785,241.05, slightly down from ¥6,280,220.20 in Q1 2021[27] - The company's fixed assets increased significantly to RMB 662.08 million from RMB 198.08 million year-on-year[23] Miscellaneous - The report for Q1 2022 was not audited, indicating that the figures may be subject to change upon final review[33]

Financial Performance - The company's operating revenue for 2021 was ¥363,386,382.24, representing a 17.93% increase compared to ¥308,145,259.54 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was -¥26,043,911.65, a decrease of 160.28% from ¥43,208,315.92 in 2020[21] - The net cash flow from operating activities was CNY 35,170,418.50, down 61.23% from CNY 90,720,874.01 in the previous year[22] - The total assets at the end of 2021 were CNY 1,258,398,896.70, representing a 29.40% increase from CNY 972,502,779.28 at the end of 2020[22] - The company's basic and diluted earnings per share were both CNY -0.17, a decline of 160.71% from CNY 0.28 in 2020[22] - The weighted average return on net assets was -3.53%, down from 5.68% in 2020[22] - In Q4 2021, the company reported a net profit attributable to shareholders of CNY -20,072,420.22, following a trend of losses in the latter half of the year[27] - The company reported a total profit loss of RMB -32,350,147.76 and a net profit loss attributable to shareholders of RMB -26,043,911.65, primarily due to rising raw material and energy costs[52] Business Operations - The company operates in the manufacturing of veterinary drugs and special chemical products, with no changes in its main business since 2018[20] - The company has engaged Lixin Certified Public Accountants as its auditing firm[21] - The company has not made any adjustments or restatements to previous years' accounting data[21] - The company has not reported any changes in its controlling shareholders since its listing[20] - The company has established stable partnerships with major clients including M.cassab, Shuanghui Development, and others, enhancing its market presence[47] - The company is focusing on the development of green and healthy veterinary raw materials and formulations to meet future market demands[53] Research and Development - The company has accumulated 17 invention patents and 15 utility model patents as of 2021, showcasing its strong commitment to research and development[45] - The company's R&D investment amounted to ¥24,821,183.37 in 2021, representing a 24.65% increase from ¥19,913,133.94 in 2020[75] - R&D personnel increased to 82 in 2021, a rise of 22.39% compared to 67 in 2020[75] - The company is currently developing several new products, including RD16 and RD19, aimed at enhancing market competitiveness and increasing sales[75] - The company is currently developing multiple new production processes aimed at optimizing costs and improving product quality[74] Market Trends and Opportunities - The global market for biopesticides is projected to grow from $3.3 billion in 2017 to $9.5 billion by 2025, with a compound annual growth rate (CAGR) of 15% to 18%[41] - The demand for safe, efficient, and low-residue veterinary drugs is increasing due to heightened food safety awareness globally, driving market growth[38] - The global population is expected to reach 8.5 billion by 2030, increasing the demand for meat, eggs, and dairy products, which benefits the animal health market[39] - The company is exploring new growth opportunities in the plant protection market amid challenges and opportunities in the agricultural sector[34] Environmental and Social Responsibility - The company has established a wastewater treatment workshop to handle wastewater, ensuring compliance with discharge standards[173] - The company reported a chemical oxygen demand (COD) discharge concentration of 21.17 mg/L, well below the standard of ≤60 mg/L[171] - The company has been actively involved in poverty alleviation, helping 17 families in 2021 with a total donation of CNY 33,400 through its charity fund[184] - The company supported rural infrastructure construction in three villages with a total funding of CNY 30,000 as part of its commitment to rural revitalization[186] - The company has implemented energy-saving measures, resulting in a continuous decrease in energy consumption indicators[180] Strategic Initiatives - The company plans to adjust the investment amount for the production project to not exceed ¥80 million, with the project expected to reach operational status by March 31, 2022[58] - The company is actively pursuing an "internal + external" growth strategy to achieve sustainable development[53] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for potential mergers and acquisitions in 2022[136] - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[130] Governance and Compliance - The company's governance structure complies with relevant regulations, ensuring independent operation and decision-making without interference from controlling shareholders[119] - The company maintains a clear ownership structure with independent assets, including land, factories, and equipment, ensuring no asset occupation by the controlling shareholder[121] - The company has established a complete independent human resources management system, with no interference from the controlling shareholder in personnel decisions[122] - The company has a fully independent supply, research and development, production, and sales system, allowing for autonomous market operations[122] Future Outlook - The company provided a positive outlook for 2022, projecting a revenue growth of 10% to 1.32 billion RMB[128] - New product launches are expected to contribute an additional 5% to revenue growth in the upcoming year, with two new products scheduled for release in Q2 2022[132] - The company aims to achieve a net profit margin of 12% by the end of 2021, up from 10% in 2020[146] - The company has set a performance guidance of 1.8 billion RMB in revenue for the next fiscal year, reflecting a 20% increase from the current year[191]